Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.
PHASE1CompletedINTERVENTIONAL
Enrollment
36
Participants
Timeline
Start Date
September 30, 2011
Primary Completion Date
March 31, 2012
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
DRUG
E5501
20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
Trial Locations (1)
85283
Celerion, Tempe
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT01437384 - Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. | Biotech Hunter | Biotech Hunter